Building TB Health Systems Capacity in High-Burden Countries
Active Since: 2013
Contributing to SDGs…
Johnson & Johnson is working with governments and other partners in TB high-burden countries to build critical health systems capacity to combat DR-TB – and TB more broadly – in support of the global community’s goal of ending TB.
Johnson & JohnsonCompany Profile
To enable countries to build health systems capacity to introduce the first novel TB medicine in nearly half a century and support the use and scale-up of the medicine in high-burden countries.
What are the health needs and challenges?
Tuberculosis (TB) is the world’s deadliest infectious disease, claiming 1.6 million lives every year. Approximately, 95% of these deaths occur in low- and middle-income countries. Growing resistance to the most commonly-used TB medicines is compounding this challenge. In fact, there are more than half a million cases of drug-resistant tuberculosis (DR-TB) every year, and DR-TB is now the leading cause of deaths from antimicrobial resistance (AMR).
DR-TB is a winnable opportunity that must urgently be addressed. Notably, only one in three cases of DR-TB is properly diagnosed, meaning that approximately 400,000 people with DR-TB don’t even know they have it. Every untreated person with DR-TB can infect up to 15 additional people every year, posing a major threat to human health and global health security.
Moreover, a recent report (2019) from the Economist Intelligence Unit, developed with support from Johnson & Johnson, showed that DR-TB also takes a massive economic toll. DR-TB deaths in a single year (i.e., 230,000 in 2017) cost the global economy $17.8 billion in future GDP loss and an additional $3 billion due to work absences.
Partnership activities and how they address needs and challenges
For several years, Johnson & Johnson has been working with governments and other partners in high-burden countries to build critical health systems capacity to combat DR-TB – and TB more broadly – in support of the global community’s goal of ending TB.
In a number of countries – including China, India, South Africa and Ukraine, among others – Johnson & Johnson is supporting a range of capacity-building activities. Areas of focus include improving access to MDR-TB treatment; training health workers on the clinical management of TB; improving local diagnostic capacity to find the “missing” patients; providing nutritional support to TB patients; and raising awareness and reducing stigma around TB at the community level.
Partnership in Action – Example from China
Since 2016, Johnson & Johnson has been partnering with China’s National Health Commission (NHC), Bill & Melinda Gates Foundation and the Chinese Center for Disease Control and Prevention (China CDC) to undertake a New Drug Introduction Program, aimed at ensuring appropriate access to Johnson & Johnson’s MDR-TB treatment.
Additionally, in 2018, Johnson & Johnson launched a collaboration with the NHC, China CDC and diagnostic manufacturer Cepheid aimed at accelerating TB and MDR-TB patient finding in poverty-stricken regions in China. The program aims at helping China achieve a two-fold increase in MDR-TB case finding in pilot areas from 2018-2021.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.3: Communicable Diseases & NTDs
- 3.C: Health workforce
- 3.D: Global health security
SDG 9: Industry Innovation and Infrastructure
SDG 17: Partnerships for the Goals
- South Africa
Infectious and Parasitic Disease
- Drug-Resistant Infections (AMR)